Curevac B.V. Stock Price, News & Analysis

CureVac N.V. reported financial results for Q2 and H1 2021, showing a cash position of €1.36 billion as of June 30. Vaccine candidate CVnCoV has demonstrated 48% efficacy across all age groups, particularly 53% in ages 18-60. A second-generation vaccine, CV2CoV, showed improved immune responses in preclinical studies and is set to enter Phase 1 trials in Q4 2021. However, total revenues decreased by 35% and 14% year-over-year due to a one-time revenue effect in 2020. Operating losses increased to €147.8 million in Q2.

CureVac has announced results from its pivotal Phase 2b/3 HERALD study of COVID-19 vaccine candidate CVnCoV, demonstrating overall vaccine efficacy of 48% against COVID-19 of any severity. The study included 40,000 participants across 10 countries and showed significant efficacy of 53% in participants aged 18 to 60. Notably, CVnCoV provided full protection against hospitalization or death in this age group. CureVac is in ongoing discussions with the European Medicines Agency (EMA) regarding regulatory submission.

CureVac N.V. (NASDAQ:CVAC) announced the appointment of Dr. Malte Greune as Chief Operating Officer effective July 1, 2021. Dr. Greune, with extensive pharmaceutical experience, will lead CureVac's clinical and commercial manufacturing initiatives. Concurrently, Dr. Florian von der Mülbe resigns from the Management Board to focus on The RNA Printer project, enhancing CureVac's mobile RNA vaccine manufacturing capabilities. Dr. Greune's leadership aims to transition CureVac from a science-driven to a commercial pharmaceutical entity, boosting its RNA-based product development.

CureVac N.V. (NASDAQ:CVAC) announced the results of its annual general meeting where shareholders approved most proposals, notably the appointments of Antony Blanc and Klaus Edvardsen as managing directors, and the re-appointment of Pierre Kemula. However, they rejected the authorization for the management board to acquire shares. The company emphasizes its focus on mRNA technology, leveraging over 20 years of expertise to develop innovative therapies across various domains.

CureVac N.V. (NASDAQ:CVAC) announced significant changes to its Supervisory Board. Dr. Ingmar Hoerr has withdrawn his candidacy due to ongoing health issues, while Dr. Timothy M. Wright has resigned to focus on personal endeavors. Both were recognized for their contributions to the company, with Hoerr credited for advancing mRNA technology. CureVac continues to develop transformative mRNA-based medicines and has a diverse clinical pipeline targeting vaccines, cancer therapies, and rare diseases. The company remains committed to its innovative approach in the biopharmaceutical sector.

CureVac (NASDAQ:CVAC) announced its second interim analysis of the HERALD study, which evaluated its COVID-19 vaccine candidate CVnCoV. Conducted across 10 countries with approximately 40,000 participants, the analysis revealed an interim efficacy of 47% against COVID-19; however, it did not meet the statistical success criteria. The safety profile remained favorable. Out of 134 assessed cases, 57% were due to variants of concern. The study is progressing towards a final analysis, with results shared with the European Medicines Agency (EMA). CureVac is also advancing second-generation vaccine candidates.

CureVac N.V. (NASDAQ:CVAC) announced the appointment of Klaus Edvardsen, MD, PhD, as Chief Development Officer, effective August 1, 2021. His extensive experience in clinical and product development, particularly in oncology, is expected to guide CureVac's transition into a fully integrated biopharmaceutical company. Edvardsen previously held senior roles at Merck KGaA and AstraZeneca, enhancing his capability to advance CureVac's mRNA technology and clinical pipeline. The company remains focused on mRNA therapeutics, including its COVID-19 vaccine candidate, CVnCoV.

CureVac announced promising preclinical results for its second-generation COVID-19 vaccine candidate, CV2CoV, developed in collaboration with GSK. The vaccine demonstrates high levels of antigen production and strong, fast-acting immune responses in rat models. Notably, CV2CoV elicited significant cross-neutralizing antibodies against variants of concern such as those from Denmark, the UK, and South Africa. The candidate is engineered for improved stability and efficacy, with clinical trials expected to commence in Q3 2021, aiming for broad protection against emerging strains.

CureVac N.V. (NASDAQ: CVAC) reported significant progress in its COVID-19 vaccine candidate CVnCoV, now in the final stage of clinical development with over 40,000 participants in a pivotal study across Europe and Latin America. The company anticipates interim efficacy data in Q2 2021. With a strong cash position of €1.32 billion as of December 31, 2020, and an additional $517.5 million raised in early 2021, CureVac is well-positioned for growth. Partnerships with Bayer, GSK, and the UK government aim to expedite vaccine development and expand production capacity to 1 billion doses by 2022.